Creative Biolabs offers efficient antibody-coupling services for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Our technology integrates advanced bioengineering and medicinal chemistry, allowing us to design and synthesize antibodies with high specificity and affinity to meet the specific requirements of our clients, and effectively couple them with pro-drug enzymes.

Introduction

ADEPT is an innovative therapeutic strategy aimed at improving the precision of drug delivery while reducing damage to healthy tissues. This therapy utilizes the unique specificity of antibodies in conjunction with the power of enzymatic reactions. By coupling antibodies to prodrugs, it facilitates the development of a range of adaptable drug formulations.

Creative Biolabs offers a comprehensive ADEPT solution, with a particular focus on antibody and pre-enzyme drug coupling services for enzyme prodrugs, providing customers with more effective and safer treatment alternatives. Our team possesses extensive experience in antibody modification and drug development. Using cutting-edge prodrug design and antibody coupling techniques, we ensure that each project is highly effective and targeted, minimizing the impact of the drug on normal cells.

Fig.1 Antibody and Prodrug Activation in Cancer Cells.^1,3

Services

Creative Biolabs has developed various ADEPT antibody coupling technology systems that enable the precise delivery of prodrugs to specific targets through their linkage with antibodies.

1. Antibody-Prodrug Release System:

Our system involves the connection of cytotoxic drugs to monoclonal antibodies, creating antibody-drug conjugates that selectively recognize tumor cell surface antigens. This enhances the targeting capability of the drugs, reduces systemic toxicity, intensifies the cytotoxic effect on tumor cells, and improves therapeutic outcomes while minimizing damage to normal cells.

2. Enzyme-Activated Antibody Conjugate System:

Our team utilizes specific enzymes present in tumor cells to convert prodrugs into active medications, allowing the antibody conjugates to release drugs within target cells. By activating tumor-specific enzymes, our technology increases the concentration of drugs inside tumor cells while limiting effects on surrounding healthy tissues, leading to more accurate therapeutic results.

3. pH or Temperature-Responsive Release System:

Creative Biolabs designs antibody conjugates that release prodrugs under specific pH or temperature conditions, enhancing the stability of drugs within the tumor microenvironment. Our system is capable of better drug release under extreme conditions, which improves both the efficiency and safety of targeted therapies.

4. Biodegradable Antibody Conjugates:

Our scientists use biocompatible and biodegradable polymers as carriers that combine with antibodies to regulate the release rate of prodrugs. This approach facilitates prolonged drug release, maintaining effective drug concentrations and reducing the frequency of administration, thereby enhancing patient compliance.

5. Antibody Conjugation with Nanotechnology:

Our lab has recently integrated antibodies with nanocarriers to improve the efficiency of drug delivery through nanoparticles. This approach enhances drug stability, solubility, and targeting capabilities, facilitating a more precise release and action of prodrugs, particularly in the complex microenvironment of tumors.

Fig.2 Antibody and Drug Coupling Strategies.^2,3

Features

Exploring the future of antibody-guided prodrug therapies, Creative Biolabs provides a wide collection of ADEPT antibody and pre-enzyme drug coupling Services. Our team boasts extensive experience and in-depth expertise, enabling us to create tailored enzyme solutions that enhance both the efficacy and safety of your pharmaceuticals.

• Flexible Coupling Design: We offer personalized coupling solutions of antibodies and enzyme prodrugs based on specific diseases and treatment requirements, ensuring that your therapeutic targets are effectively addressed.
• Efficient Coupling Technology: Using leading coupling techniques, we enhance the efficiency of antibody and enzyme prodrug binding, guaranteeing the effective release of active medications within the body.
• Quality Assurance: Our rigorous quality monitoring system ensures that each batch of coupling products meets international standards, providing reliable support for both research and clinical applications.
• Expert Team: Our research and development team boasts extensive experience and expertise, dedicated to the continuous optimization and advancement of antibody coupling technologies, ensuring that clients receive the latest scientific developments and technical assistance.
• Controlled Drug Release: By selecting appropriate linkers, antibodies, and pre-enzyme drug conjugates can be cleaved by specific enzymes within the target cells, resulting in the safe release of active drugs. This precise release mechanism ensures that the medication acts at the right time and location, minimizing damage to healthy cells.
• Enhanced Immune Response: Our antibody and pre-enzyme drug coupling products not only focus on tumor cells but also stimulate the body's immune system, improving its ability to monitor and eliminate tumors, thereby increasing the overall effectiveness of the treatment.
• Reduced Drug Resistance: By exploring and utilizing various mechanisms and targets in the design of antibody and pre-enzyme drug coupling, it is possible to effectively address the common issue of drug resistance.

Creative Biolabs can provide our clients with top-tier services in ADEPT enzyme prodrug and antibody coupling solutions to support the development of innovative therapeutic solutions. Our cutting-edge antibody coupling platform enables the efficient synthesis and optimization of antibodies and enzyme prodrugs conjugates. We warmly invite you to contact us to discuss your enzyme prodrug and antibody conjugation project needs.

References

1. Yao, Qingxin, et al. "Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems." Nature Communications 9.1 (2018): 5032.
2. El Alaoui, Meddy, et al. "Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase." Cell death discovery 10.1 (2024): 79.
3. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use